High-Content Surface and Total Expression siRNA Kinase Library Screen with VX-809 Treatment Reveals Kinase Targets that Enhance F508del-CFTR Rescue

• DOI: 10.1021/acs.molpharmaceut.7b00928
• Publication Date: 2018-01-31T16:02:19Z
• Authors: Lydia A. Perkins; Gregory W. Fisher; Matharishwan Naga...; Brigitte F. Schmidt; Frederick Mun; Marcel P. Bruchez
• Keywords: 0303 health sciences; Cystic Fibrosis; Cell Membrane; Phosphotransferases; Drug Evaluation, Preclinical; Aminopyridines; Cystic Fibrosis Transmembrane Conductance Regulator; Drug Synergism; Flow Cytometry; High-Throughput Screening Assays; 03 medical and health sciences; HEK293 Cells; Treatment Outcome; Gene Knockdown Techniques; Mutation; Humans; Drug Therapy, Combination; Benzodioxoles; RNA, Small Interfering; Protein Kinase Inhibitors; Fluorescent Dyes

The most promising F508del-CFTR corrector, VX-809, has been unsuccessful as an effective, stand-alone treatment for CF patients, but the rescue effect in combination with other drugs may confer an acceptable level of therapeutic benefit. Targeting cellular factors that modify trafficking may act to enhance the cell surface density of F508-CFTR with VX-809 correction. Our goal is to identify druggable kinases that enhance F508del-CFTR rescue and stabilization at the cell surface beyond that achievable with the VX-809 corrector alone. To achieve this goal, we implemented a new high-throughput screening paradigm that quickly and quantitatively measures surface density and total protein in the same cells. This allowed for rapid screening for increased surface targeting and proteostatic regulation. The assay utilizes fluorogen-activating-protein (FAP) technology with cell excluded and cell permeant fluorogenic dyes in a quick, wash-free fluorescent plate reader format on live cells to first measure F508del-CFTR expressed on the surface and then the total amount of F508del-CFTR protein present. To screen for kinase targets, we used Dharmacon's ON-TARGET plus SMARTpool siRNA Kinase library (715 target kinases) with and without 10 μM VX-809 treatment in triplicate at 37 °C. We identified several targets that had a significant interaction with VX-809 treatment in enhancing surface density with siRNA knockdown. Select small-molecule inhibitors of the kinase targets demonstrated augmented surface expression with VX-809 treatment.